SVRA - Savara Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.24
+0.04 (+0.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.20
Open11.29
Bid0.00 x 900
Ask0.00 x 1100
Day's Range11.13 - 11.32
52 Week Range7.85 - 17.19
Volume69,018
Avg. Volume256,175
Market Cap394.46M
Beta0.10
PE Ratio (TTM)N/A
EPS (TTM)-1.81
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.43
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update

    Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018 AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019 Molgradex Phase 2 a OPTIMA study enrollment on track ...

  • ACCESSWIRElast month

    Savara, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Savara, Inc. (NASDAQ: SVRA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:30 PM Eastern Time. To listen ...

  • GlobeNewswire2 months ago

    Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018

    AUSTIN, Texas, Aug. 02, 2018-- Savara Inc., an orphan lung disease company, today announced it will release its second quarter 2018 financial results on Thursday, August 9, 2018. Savara management will ...

  • Philadelphia Angel Group Keiretsu Joins Orphan Lung Disease Company, Savara, as It Rings Nasdaq Opening Bell
    Newsfile2 months ago

    Philadelphia Angel Group Keiretsu Joins Orphan Lung Disease Company, Savara, as It Rings Nasdaq Opening Bell

    Howard Lubert, President of the Keiretsu Forum Mid-Atlantic, a global angel investor network, joined Rob Neville CEO of Savara on Monday, June 23, 2018, to ring the Opening Bell at Nasdaq MarketSite. Philadelphia, Pennsylvania--(Newsfile Corp. - July 26, 2018) - Howard Lubert, President of the Keiretsu Forum Mid-Atlantic, a global angel investor network, joined Rob Neville CEO of Savara, (Nasdaq: SVRA), an orphan lung disease company, as they rang the Opening Bell at the ...

  • GlobeNewswire2 months ago

    Savara Announces Pricing of Public Offering of Common Stock

    Savara Inc. (SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $11.50 per share. In addition, Savara has granted the underwriters a 30-day option to purchase up to 637,500 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. Savara intends to use the net proceeds from this offering for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of and pursuing regulatory approval for its product candidates (including the expansion of the Molgradex NTM program with a new study in the U.S. in CF affected individuals with chronic NTM lung infection), the initiation of Molgradex pre-commercialization activities, and general and administrative expenses.

  • GlobeNewswire2 months ago

    Savara Announces Proposed Public Offering of Common Stock

    Savara Inc. (SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Savara intends to use the net proceeds from this offering for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of and pursuing regulatory approval for its product candidates (including the expansion of the Molgradex NTM program with a new study in the U.S. in CF affected individuals with chronic NTM lung infection), the initiation of Molgradex pre-commercialization activities, and general and administrative expenses. Savara may also use the net proceeds of the offering to acquire products, technologies or companies that we believe will further our strategic initiatives, although we currently have no agreements, commitments or understandings with respect to any such transaction.

  • GlobeNewswire2 months ago

    Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF

    Savara Inc. (SVRA), an orphan lung disease company, today provided an update on the clinical development and commercial preparatory efforts for its lead product candidate Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). In addition, Savara is expanding its Molgradex nontuberculous mycobacteria (NTM) program with a new study in the U.S. in cystic fibrosis (CF) affected individuals with chronic NTM lung infection. The Company also announced its acquisition of the assets of Cardeas Pharma Corporation as part of its launch of an exploratory product pipeline comprising pre-proof-of-concept, high-potential programs focused on difficult-to-treat lung diseases, and the appointment of Dr. A. Bruce Montgomery as a strategic advisor.

  • GlobeNewswire2 months ago

    Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd

    Savara Inc. (SVRA), an orphan lung disease company, announced today that Rob Neville, CEO of Savara, alongside key members of senior management, company directors, and employees, will ring the Nasdaq Stock Market Opening Bell today, July 23rd 2018. “It is an honor to be ringing the Nasdaq Opening Bell, which commemorates almost a decade of dedication by our team in our pursuit of developing medicines for patients suffering from rare lung diseases,” said Rob Neville, CEO of Savara. “With two ongoing pivotal clinical trials (IMPALA and AVAIL), a Phase 2a clinical trial in NTM (OPTIMA), and patient enrollment in all our studies proceeding on schedule, we have a number of important clinical trial data readouts expected over the next year.

  • GlobeNewswire3 months ago

    Savara Joins Russell 3000® Index

    Savara Inc. (SVRA), an orphan lung disease company, announced today that the company has been added to the broad-market Russell 3000 Index. “In the little more than one year since transitioning to the public markets, Savara’s inclusion in the Russell 3000 Index marks another milestone reflecting the significant progress we have made toward building a leading orphan lung disease company,” stated Rob Neville, chief executive officer of Savara. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11, 2018, ranking them by total market capitalization.

  • American City Business Journals3 months ago

    Dive into the latest metric to compare Austin public companies: CEO pay ratios

    Because of the 2010 Dodd-Frank Act, public companies must reveal how much they pay their CEO versus the median employee. Here is a look at how Austin companies compare, with an interactive graphic showing specific CEO salary levels.

  • Why Savara Inc. Is Soaring Today
    Motley Fool3 months ago

    Why Savara Inc. Is Soaring Today

    Traders cheer after the company receives positive analyst coverage. Here's what investors need to know.

  • Marketwired5 months ago

    Savara to Host First Quarter 2018 Financial Results and Business Update Conference Call on Wednesday, May 9, 2018

    AUSTIN, TX--(Marketwired - May 01, 2018) - Savara Inc. (SVRA), an orphan lung disease company, today announced it will release its first quarter 2018 financial results on Wednesday, May 9, 2018. Savara management will also host a conference call for investors beginning at 5:30 p.m. ET on Wednesday, May 9, 2018 to discuss its first quarter 2018 financial results and to provide a business update. Shareholders and other interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the Savara Inc. call.

  • Marketwired6 months ago

    Savara to Present at 28th Annual Oppenheimer & Co. Healthcare Conference on March 20th

    Savara Inc. , an orphan lung disease company, announced today that the Company's Chief Executive Officer, Rob Neville, will present at the 28th Annual Oppenheimer & Co. Healthcare Conference on Tuesday, ...

  • Associated Press6 months ago

    Mast reports 4Q loss

    On a per-share basis, the Austin, Texas-based company said it had a loss of 23 cents. For the year, the company reported that its loss narrowed to $30.8 million, or $1.76 per share. Mast shares have dropped ...

  • Marketwired6 months ago

    Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

    Anticipating completion of enrollment in Molgradex Phase 3 IMPALA study in Q3 2018Anticipating completion of enrollment in AeroVanc Phase 3 AVAIL study in Q1 2019Anticipating completion of enrollment in ...

  • Marketwired6 months ago

    Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection

    Savara Inc. , an orphan lung disease company, announced today the initiation of a Phase 2a clinical study, OPTIMA, evaluating its lead product candidate Molgradex, an inhaled formulation of recombinant ...

  • Savara Inc (NASDAQ:SVRA): When Will It Breakeven?
    Simply Wall St.6 months ago

    Savara Inc (NASDAQ:SVRA): When Will It Breakeven?

    Savara Inc’s (NASDAQ:SVRA): Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. TheRead More...

  • Marketwired6 months ago

    Aironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research Network

    Savara Inc. , an orphan lung disease company, today announced results from the INDIE study of Aironite evaluating the use of inhaled inorganic nitrite for symptom relief in patients with heart...